The Atomic Energy Organization of Iran (AEOI) has unveiled its latest diagnostic radiopharmaceutical for prostate cancer.

According to The Iran Project,The medicinal radiocompound was unveiled on Sunday at the second exhibition of knowledge-based products in the food, pharmaceutical, and medical equipment sector in the presence of the AEOI chief Mohammad Eslami and health minister Bahram Einollahi.

The new radiopharmaceutical, named PARS-TECTO-PSMA, was introduced by Pars Isotope Company.

Synthesized and formulated for the first time by domestic experts, the kit provides the capability for faster and more cost-effective prostate cancer diagnosis in the early stages using a new imaging method called SPECT (Single Photon Emission Computed Tomography).

The radiopharmaceutical specifically attaches to prostate cancer receptors in the body, offering more accurate information to the treating physician about the size and location of the tumor compared to previous methods.

The innovation enhances the monitoring and observation of the patient's recovery process as well.